Zyceva 150 Tablet: A Powerful Treatment Option for Non-Small Cell Lung Cancer

Zyceva 150 Tablet contains Erlotinib, a potent tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC). This medication acts by blocking the activity of specific protein enzymes involved in tumor growth. Specifically, it targets the epidermal growth factor receptor (EGFR) pathway, which is often overactive in NSCLC cells.

Zyceva 150 Tablet has been proven effective in shrinking tumors and improving survival rates for patients with advanced NSCLC who have a history of specific EGFR mutations. It is typically prescribed alongside other treatments, like chemotherapy or radiotherapy, to address the disease's complexity.

Important Information:
This medication should only be taken as directed by your healthcare professional. It may cause side effects, such as diarrhea, nausea, vomiting, and dry mouth. Always follow your physician’s instructions regarding dosage and any potential side effect management.

Consult with a doctor before starting this medication to ensure it is safe for you.